Zai Lab's AUGTYRO For ROS1+ NSCLC Added To China's National Reimbursement Drug List
28/11 06:45
(RTTNews) - Zai Lab Limited (ZLAB) announced the inclusion of AUGTYRO (repotrectinib) in China's National Reimbursement Drug List for ROS1+ non-small cell lung cancer or NSCLC. The company also shared additional updates regarding the reimbursement list....